Twist Bioscience (NASDAQ:TWST) CEO Emily M. Leproust Sells 2,265 Shares

Key Points

• Emily Leproust, CEO of Twist Bioscience, sold 2,265 shares at an average price of $25.76, totaling approximately $58,346, which represents a 0.36% decrease in her position.
• Twist Bioscience's stock is currently trading at $25.09, with a market cap of $1.51 billion and a fifty-two week low of $24.28.
• Twist Bioscience reported a quarterly earnings per share of (-$0.47), surpassing analyst expectations, and has received an average rating of "Moderate Buy" from research analysts.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 2,265 shares of Twist Bioscience stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $25.76, for a total value of $58,346.40. Following the transaction, the chief executive officer owned 634,740 shares in the company, valued at approximately $16,350,902.40. This represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Twist Bioscience Stock Up 1.2%

Shares of Twist Bioscience stock traded up $0.31 during trading on Monday, reaching $25.62. The stock had a trading volume of 814,952 shares, compared to its average volume of 1,211,592. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -17.67 and a beta of 2.31. The stock has a fifty day moving average price of $30.52 and a two-hundred day moving average price of $34.18. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of recent research reports. Evercore ISI set a $46.00 target price on Twist Bioscience in a research report on Monday, August 4th. Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Institutional Trading of Twist Bioscience

A number of large investors have recently bought and sold shares of the business. Osaic Holdings Inc. grew its holdings in Twist Bioscience by 31.6% during the 2nd quarter. Osaic Holdings Inc. now owns 7,054 shares of the company's stock worth $261,000 after acquiring an additional 1,694 shares during the period. Squarepoint Ops LLC grew its stake in shares of Twist Bioscience by 192.8% in the 2nd quarter. Squarepoint Ops LLC now owns 71,708 shares of the company's stock valued at $2,638,000 after buying an additional 47,221 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $97,000. Soleus Capital Management L.P. acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $13,038,000. Finally, Man Group plc grew its stake in shares of Twist Bioscience by 5.3% in the 2nd quarter. Man Group plc now owns 106,509 shares of the company's stock valued at $3,918,000 after buying an additional 5,348 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.